The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.

M LebwohlA DeodharChristopher Ernest Maitland GriffithsM A MenterD PoddubnyyW BaoV JehlK MarfoP PrimatestaA SheteV TrivediP J Mease

Published in: The British journal of dermatology (2021)

In this large safety analysis, the risk of malignancy was low for up to 5 years of secukinumab treatment. These data support the long-term use of secukinumab in these indications.

Keyphrases

ankylosing spondylitis
clinical trial
disease activity
rheumatoid arthritis
electronic health record
big data
public health
systemic lupus erythematosus
open label
data analysis
study protocol
phase ii
combination therapy
double blind
machine learning
deep learning
artificial intelligence